Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
BCL2L11 (BCL2 Like 11)
i
Other names:
BCL2L11, BCL2 Like 11, BIM, BCL2-Like 11 (Apoptosis Facilitator), Bcl-2-Like Protein 11, BOD, Bcl-2 Interacting Mediator Of Cell Death, Bcl2-Interacting Mediator Of Cell Death, Bcl-2-Related Ovarian Death Agonist, Bcl-2 Interacting Protein Bim, Bcl2-L-11, BCL2L11, BimEL, BimL, BimS, BAM
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
10018
Related tests:
‹
Tempus xT Assay (1)
OncoGuide™ NCC Oncopanel System
Tempus xT Assay (1)
OncoGuide™ NCC Oncopanel System
›
Associations
(7)
News
Trials
VERI cancer hierarchy
Reset Filters
BCL2L11 deletion + EGFR T790M
Non Small Cell Lung Cancer
BCL2L11 deletion + EGFR T790M
Non Small Cell Lung Cancer
osimertinib
Resistant: C3 – Early Trials
osimertinib
Resistant
:
C3
osimertinib
Resistant: C3 – Early Trials
osimertinib
Resistant
:
C3
BCL2L11 deletion + ALK positive
Non Small Cell Lung Cancer
BCL2L11 deletion + ALK positive
Non Small Cell Lung Cancer
crizotinib
Resistant: C3 – Early Trials
crizotinib
Resistant
:
C3
crizotinib
Resistant: C3 – Early Trials
crizotinib
Resistant
:
C3
EGFR mutation + BCL2L11 deletion
Non Small Cell Lung Cancer
EGFR mutation + BCL2L11 deletion
Non Small Cell Lung Cancer
bevacizumab
Sensitive: C3 – Early Trials
bevacizumab
Sensitive
:
C3
bevacizumab
Sensitive: C3 – Early Trials
bevacizumab
Sensitive
:
C3
EGFR mutation + BCL2L11 deletion
Non Small Cell Lung Cancer
EGFR mutation + BCL2L11 deletion
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR inhibitor
Resistant
:
C3
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR inhibitor
Resistant
:
C3
EGFR mutation + BCL2L11 overexpression
Non Small Cell Lung Cancer
EGFR mutation + BCL2L11 overexpression
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR inhibitor
Resistant
:
C3
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR inhibitor
Resistant
:
C3
BCL2L11 underexpression
Multiple Myeloma
BCL2L11 underexpression
Multiple Myeloma
venetoclax
Resistant: D – Preclinical
venetoclax
Resistant
:
D
venetoclax
Resistant: D – Preclinical
venetoclax
Resistant
:
D
BCL2L11 overexpression
Squamous Cell Carcinoma of Head and Neck
BCL2L11 overexpression
Squamous Cell Carcinoma of Head and Neck
cisplatin
Resistant: D – Preclinical
cisplatin
Resistant
:
D
cisplatin
Resistant: D – Preclinical
cisplatin
Resistant
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.